T1	Participants 50 79	chronic lymphocytic leukemia.
T2	Participants 175 230	patient outcomes in chronic lymphocytic leukemia (CLL).
T3	Participants 277 375	patients who will benefit from immunochemotherapy over chemotherapy alone has not been determined.
T4	Participants 376 519	We assessed genome-wide expression of 300 pretreatment specimens from a subset of 552 patients in REACH, a study of FC or R-FC in relapsed CLL.
T5	Participants 520 650	An independent test set was derived from 282 pretreatment specimens from CLL8, a study of FC or R-FC in treatment-na√Øve patients.
T6	Participants 1314 1330	for CLL patients
